Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647436 | 1.00 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| SCHEMBL10092899 | 1.00 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| Azd-6088 SCHEMBL649526 | 0.94 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| Azd-6088 SCHEMBL647335 | 0.94 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| Azd-6088 SCHEMBL648601 | 0.94 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| Azd-6088 SCHEMBL649525 | 0.94 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| Azd-6088 SCHEMBL649524 | 0.94 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| SCHEMBL649273 | 0.90 | OPRL1 (0.41) | OPRL1OPRM1OPRK1OPRD1CHRM4 | |
| SCHEMBL649192 | 0.90 | OPRL1 (0.45) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| SCHEMBL647249 | 0.89 | OPRL1 (0.40) | OPRL1OPRM1OPRK1OPRD1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | claimed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | AstraZeneca AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076078-A1 | New compounds 966 | OPRM1, OPRL1, OPRK1 | OPRL1 2/4885OPRM1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.